Observational study testing enhanced CBD formulation
Avecho’s (ASX:AVE) plan to develop cannabidiol (CBD) products enhanced by our TPM® technology has the capacity to transform the efficiency and effectiveness of a range of products – and today, I am pleased to report an important milestone on our path to generate the necessary, high quality evidence to support this.
Our Company is now participating in the CA Clinics Observational Study (CACOS), Australia’s largest running observational study of medicinal cannabis products. Our goal is to test the performance of our enhanced oral cannabidiol (CBD) TPM® formulation in human patients being prescribed medicinal cannabis for a range of indications.
About the study:
- Avecho’s oral CBD TPM® formulation has already demonstrated a capacity to increase the oral bioavailability of CBD in animal models.
- As part of the CACOS study, we will gather real world feedback on how this product performs in patients for a range of indications that currently utilise medicinal cannabis therapy. Performance will be compared against commonly prescribed medicinal cannabis formulations.
- Recruitment for the study will be ongoing over the next year, with the intent to maximise the number of patients dosed with both the CBD TPM® and commercial comparator formulations.
– Dr Paul Gavin, Avecho Chief Executive Officer